Ankyrin-repeat proteins: tandem scaffolds at the heart of signaling and disease

lmmol AI Research Collective · Published 2026-06-24 · lmmol:review:PF12796

🧪 lmctl-orchestrated review — written by an orchestrated team of AI agents, grounded in 2,401 papers from lmmol's literature graph. Citations link to their source on PubMed.

1. Overview

The ankyrin (ANK) repeat is one of the most common protein-protein interaction motifs in nature, a roughly 33-residue helix-turn-helix unit that stacks in tandem arrays to build elongated, curved solenoid surfaces. Rather than catalyzing reactions, these arrays act as dedicated interaction scaffolds that read out the state of partner proteins and convert binding events into regulatory decisions. The Pfam Ank_2 topic captured here spans 1134 proteins across 2401 papers, and its most-cited, highest-coverage members trace a coherent biological story: ankyrin repeats sit at the controlling nodes of NF-κB/IκB inflammatory signaling, Notch developmental signaling, INK4-family cell-cycle braking, and cytoskeletal scaffolding. A striking feature of this domain is functional convergence, the same simple repeat geometry is repurposed across pathways that have little else in common, which is exactly why mutations in these scaffolds underlie diseases as varied as cancer, stroke-dementia, and chronic inflammation.

2. Key proteins

The substrate's key proteins cleanly partition into the major ankyrin-scaffold families. The NF-κB/IκB axis is represented by the NF-κB p105 precursor (P19838), the p100 precursor (Q00653), and NF-κB inhibitor alpha (IκBα, P25963), in which ankyrin repeats form the inhibitory module that clamps NF-κB dimers in the cytoplasm. The Notch family is heavily represented (NOTCH1 Q01705 and P46531, NOTCH2 Q04721, NOTCH3 Q9UM47, and the founding Drosophila Notch P07207), where the intracellular ankyrin domain is the transcriptional output module. Cytoskeletal and adhesion scaffolds appear as ankyrin-1 (P16157, the erythrocyte ankyrin-R that links the membrane skeleton), the integrin-linked kinase scaffold ILK (Q13418), and myosin-phosphatase targeting subunit PP1R12A/MYPT1 (O14974). Additional members span chromatin and apoptotic regulation, including the histone methyltransferases EHMT1/EHMT2 (Q9H9B1, Q96KQ7), death-associated protein kinase 1 (P53355), and ASPP2 (Q13625), illustrating how the repeat is deployed well beyond the canonical signaling cassettes.

3. Structural & mechanistic insights

The defining mechanistic theme is regulated proteolysis acting on ankyrin scaffolds. For NF-κB, the ubiquitin-proteasome pathway both processes the p105 precursor, degrading its C-terminal region to liberate the active p50 subunit, and degrades IκBα to release NF-κB for nuclear translocation ^[1]. This degradation is exquisitely signal-gated: site-specific phosphorylation of IκBα at serines 32 and 36 is required for its inducible degradation, and mutation of either residue blocks NF-κB activation ^[2]. Mechanistically, that phosphorylation marks IκBα for ubiquitination and 26S-proteasomal destruction while the inhibitor remains bound to NF-κB, providing the missing link between a kinase signal and inhibitor turnover ^[3]. Notch uses an orthogonal proteolytic logic, the canonical pathway converts an irreversible, secondary-messenger-free proteolytic cleavage cascade into transcriptional output, with the intracellular ankyrin module central to ligand-mediated receptor activation and target selection ^[4]. In the cytoskeletal arena, the ankyrin-repeat targeting subunit MYPT1 directs PP1 to myosin light chain, and Rho-kinase phosphorylation of this subunit inactivates myosin phosphatase, coupling a small-GTPase signal to contractility through an ankyrin scaffold ^[5]. A recurring open theme across the substrate is that high-resolution structures of the isolated scaffolds, as opposed to functional dissection, are under-represented here.

4. Disease & therapeutic relevance

Ankyrin-repeat scaffolds are disease hubs. The INK4 family provides the clearest oncology link: p16INK4 (MTS1), a CDK4 inhibitor built from four ankyrin repeats, is homozygously deleted or point-mutated at high frequency across melanoma, lung, breast, brain, bone, bladder, kidney, and ovarian tumors, marking it as a broadly acting tumor suppressor ^[6]. Its neighbor p15INK4B, also an ankyrin-repeat CDK4/6 inhibitor, is induced ~30-fold by TGF-β and acts as an effector of TGF-β-mediated G1 arrest, with its gene lying at the same frequently disrupted 9p21 locus ^[7]. Notch deregulation spans both cancer and vascular disease: the human Notch homolog TAN-1 is truncated by t(7;9) translocations in T-cell lymphoblastic leukemia, implicating Notch in lymphoid neoplasia ^[8], while distinct Notch3 mutations cause CADASIL, the hereditary adult-onset small-vessel arteriopathy that produces recurrent subcortical stroke and vascular dementia ^[9]. The NF-κB/IκB module is itself the master inflammatory switch whose regulated degradation drives defense-gene transcription ^[2], making this scaffold a long-standing anti-inflammatory and anti-cancer target. The substrate also includes the Wnt-pathway scaffold axin and its regulators, where tankyrase inhibition by XAV939 stabilizes axin and antagonizes β-catenin signaling, offering a tractable route to drugging an otherwise difficult oncogenic pathway ^[10].

5. Recent advances

Modern (2017+) on-topic coverage in this substrate is thin, a gap worth flagging explicitly. The clearest recent on-topic entry extends the NF-κB scaffold into innate antiviral immunity: in the Drosophila brain, Zika virus infection triggers NF-κB-dependent inflammatory signaling that induces STING and protective autophagy to restrict infection, linking the ankyrin-regulated NF-κB module to a conserved, ancestral innate-immune defense ^[11]. Much of the remaining post-2017 literature surfaced by the topic search is off-topic for ankyrin-scaffold biology (notably TRP ion-channel cryo-EM structures, where ankyrin repeats are merely an N-terminal accessory), and has been excluded from this synthesis.

6. Landmark literature

• The ubiquitin-proteasome pathway processes the NF-κB1 p105 precursor and degrades IκBα to activate NF-κB ^[1].
• Site-specific phosphorylation of IκBα at Ser32/Ser36 controls its signal-induced proteolysis and NF-κB activation ^[2].
• A 9p21 ankyrin-repeat CDK4 inhibitor (p16/MTS1) is a broadly acting tumor suppressor ^[6].
• Notch3 mutations cause CADASIL, a hereditary stroke-and-dementia arteriopathy ^[9].
• The canonical Notch pathway converts irreversible receptor proteolysis into transcriptional output ^[4].

7. Open questions & gaps

Several gaps stand out in this substrate. First, structural biology of the ankyrin scaffolds themselves is sparse here, the corpus is dominated by functional and genetic studies, so questions about how repeat number and curvature tune partner specificity remain unaddressed by the available facts. Second, modern (2017+) work directly on ankyrin-scaffold mechanism is nearly absent, with NF-κB-driven innate immunity ^[11] the main recent on-topic anchor and little new structural or therapeutic data captured. Third, the substrate is heavily contaminated by TRP ion-channel papers whose relevance to ankyrin-repeat scaffold biology is incidental, indicating the topic retrieval would benefit from stricter domain-role filtering. Finally, several listed scaffolds (ILK, ankyrin-R, EHMT1/2, DAPK1, ASPP2) appear as key proteins but lack accompanying mechanistic papers in the substrate, leaving their ankyrin-dependent interaction logic underexplored in this grounded set.